Mavyret generic
Mavyret is an antiviral drug owned by Abbvie Inc. It has two active ingredients, Glecaprevir and Pibrentasvir. The drug was first authorized for market use on August 3, 2017, and currently holds 20 patents.
When will Mavyret generic be available?
The generic version of Mavyret can potentially be released after December 24, 2036. This date is based on the expiry date of the last patent held for this drug.
Mavyret uses
Mavyret is primarily used as a treatment for chronic hepatitis C virus (HCV). It is effective against HCV genotypes 1, 2, 3, 4, 5, and 6. It can be used in pediatric patients aged between 3 to 12 years or those weighing less than 45 kg, as well as in adults and pediatric patients who are 12 years and older or weigh at least 45 kg.
Mavyret patent expiration
Mavyret holds a total of 20 patents, with none expired so far. The patents cover aspects ranging from antiviral compounds to methods for treating HCV and solid pharmaceutical compositions. The last Mavyret patent is expected to expire on December 24, 2036. Detailed patent information is provided below.